RGNX
REGENXBIO Inc.
$7.80
-$0.10(-1.27%)
52
Overall
40
Value
70
Tech
47
Quality
Market Cap
$358.26M
Volume
3.21M
52W Range
$5.46 - $16.19
Target Price
$25.58
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $4.6M | $10.4M | $218.5M | $35.2M | $154.6M | $470.3M | $112.7M | $90.2M | $83.3M | $170.4M | ||
| Total Revenue | $4.6M | $10.4M | $218.5M | $35.2M | $154.6M | $470.3M | $112.7M | $90.2M | $83.3M | $170.4M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-98.0K | $-1.7M | $-9.6M | $8.2M | $35.7M | $51.8M | $54.5M | $37.2M | $33.6M | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $3.6M | $8.7M | $208.9M | $27.0M | $118.9M | $418.5M | $58.2M | $53.0M | $83.3M | $170.4M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $69.0M | $84.6M | $120.8M | $176.0M | $230.1M | $260.8M | $321.1M | $320.8M | $285.1M | $311.2M | ||
| Research & Development | $45.5M | $57.2M | $83.9M | $124.2M | $166.3M | $181.4M | $242.5M | $232.3M | $208.5M | $228.3M | ||
| Research Expense | $45.5M | $57.2M | $83.9M | $124.2M | $166.3M | $181.4M | $242.5M | $232.3M | $208.5M | $228.3M | ||
| Selling, General & Administrative | $23.6M | $27.2M | $36.9M | $51.8M | $63.8M | $79.3M | $85.3M | $88.5M | $76.6M | $82.9M | ||
| General & Administrative Expenses | $23.6M | $27.2M | $36.9M | $51.8M | $63.8M | $79.3M | $85.3M | $88.5M | $76.6M | $82.9M | ||
| Salaries & Wages | $-7.0M | $-10.6M | $-16.6M | -- | -- | -- | $40.8M | $40.3M | $38.5M | -- | ||
| Depreciation & Amortization | $-544.0K | $-2.7M | $-4.0M | $7.2M | $8.4M | $9.6M | $12.9M | $17.3M | $16.2M | -- | ||
| Depreciation & Amortization | $-544.0K | $-2.7M | $-4.0M | $7.2M | $8.4M | $9.6M | $12.9M | $17.3M | $16.2M | -- | ||
| Other Operating Expenses | $-102.0K | $116.0K | $42.0K | $3.7M | $6.3M | $12.1M | $11.3M | $13.4M | $13.6M | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-65.3M | $-75.9M | $88.1M | $-149.0M | $-119.2M | $160.0M | $-262.9M | $-268.1M | $-233.3M | $-161.2M | ||
| EBITDA | $-60.9M | $-68.7M | $108.9M | $-91.5M | $-96.8M | $177.1M | $-244.3M | $-246.3M | $-198.2M | $-133.3M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | $771.0K | $26.3M | $23.3M | $6.9M | $12.7M | $45.0M | ||
| Intinc | -- | -- | $8.9M | -- | -- | -- | -- | $9.1M | $174.0K | -- | ||
| Net Non-Operating Interest Income/Expense | $1.9M | $2.7M | $16.0M | -- | $-771.0K | $-23.7M | $22.9M | $9.1M | $-7.7M | $-45.0M | ||
| Gain on Sale of Securities | -- | $479.0K | $-39.0K | $48.6M | $9.7M | $6.8M | $5.4M | $11.3M | $18.7M | $12.2M | ||
| Other Income/Expense | -- | $-479.0K | $-176.1M | $-51.5M | $-14.0M | $-7.5M | $5.4M | $-11.3M | $-18.7M | $-12.2M | ||
| Other Special Charges | -- | -- | $176.1M | $3.0M | $4.3M | $719.0K | -- | -- | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | $3.7M | $400.0K | -- | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | $-7.5M | $-3.7M | $-2.1M | -- | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | $2.1M | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-63.4M | $-73.2M | $104.1M | $-97.5M | $-105.2M | $167.5M | $-257.2M | $-263.6M | $-214.4M | $-148.9M | ||
| Pre-Tax Income | $-63.4M | $-73.2M | $104.1M | $-97.5M | $-106.0M | $141.2M | $-280.4M | $-263.6M | $-192.8M | $-173.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-435.0K | $-16.6M | $4.2M | $-2.8M | $5.2M | $13.4M | $-84.0K | $-152.0K | $-10.7M | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-63.0M | $-73.2M | $99.9M | $-94.7M | $-111.3M | $127.8M | $-280.3M | $-263.5M | $-227.1M | $-193.9M | ||
| Net Income (Continuing Operations) | $-63.0M | $-73.2M | $99.9M | $-94.7M | $-111.3M | $127.8M | $-280.3M | $-263.5M | $-227.1M | $-193.9M | ||
| Net Income (Discontinued Operations) | $-63.0M | $-73.2M | $99.9M | $-94.7M | $-111.3M | $127.8M | $-280.3M | $-263.5M | $-227.1M | $-193.9M | ||
| Net Income (Common Stockholders) | $-63.0M | $-73.2M | $99.9M | $-94.8M | $-111.3M | $127.8M | $-280.3M | $-263.5M | $-192.8M | $-193.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-171.7M | ||
| TOTALS | ||||||||||||
| Total Expenses | $68.9M | $82.9M | $111.1M | $184.2M | $265.8M | $312.6M | $375.6M | $358.0M | $285.1M | $311.2M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $26.4M | $29.9M | $33.4M | $36.7M | $37.3M | $42.4M | $43.2M | $43.7M | $49.5M | $51.6M | ||
| Average Shares Outstanding (Diluted) | $26.5M | $29.9M | $36.6M | $36.7M | $37.3M | $43.9M | $43.2M | $43.7M | $49.5M | $51.6M | ||
| Shares Outstanding | $26.5M | $31.7M | $36.4M | $37.1M | $42.5M | $42.9M | $43.5M | $44.4M | $50.1M | $51.6M | ||
| Basic EPS | -- | -- | $2.99 | $-2.58 | $-2.98 | $3.01 | $-6.5 | $-6.02 | $-4.59 | $-3.76 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-2.58 | $-2.98 | $3.01 | $-6.5 | $-6.02 | $-4.59 | $-3.76 | ||
| Diluted EPS | $-2.38 | $-2.45 | $2.73 | $-2.58 | $-2.98 | $2.91 | $-6.5 | $-6.02 | $-4.59 | $-3.76 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-2.58 | $-2.98 | $2.91 | $-6.5 | $-6.02 | $-4.59 | $-3.76 | ||
| OTHER METRICS | ||||||||||||
| Non Recurring Operation Expense | -- | -- | -- | -- | -- | -- | $7.5M | $7.5M | $7.5M | -- | ||
| Other Gand A | $23.6M | $27.2M | $36.9M | $51.8M | $63.8M | $79.3M | $85.3M | $88.5M | $76.6M | $82.9M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | $2.1M | -- | ||
| Rent And Landing Fees | $23.6M | $27.2M | $36.9M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | $3.7M | $400.0K | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RGNX | $7.80 | -1.3% | 3.21M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |